产品描述: | MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2 |
靶点: |
Chk1(Cell-free assay):3 nM; CDK2(Cell-free assay):0.16 μM;Chk; CDK |
体外研究: |
SCH 900776是Chk2和CDK2的低效抑制剂,IC50分别为1.5 μM 和 0.16 μM。SCH 900776对细胞色素P450人肝微粒体亚型1A2,2C9,2C19,2D6,和3A4没有显著的抑制作用。羟基脲下暴露24小时后,SCH 900776诱导DNA复制能力剂量依赖性损失。SCH 900776增强γ-H2AX对羟基脲,5-氟尿嘧啶,和阿糖孢苷的响应。与抗代谢物结合,SCH 900776在2小时内诱导γ-H2AX的累积,表明复制叉瓦解,并且双链DNA断裂。此外,SCH 900776以剂量依赖的方式抑制Chk1 pS296自磷酸化的积累。增殖的WS1细胞暴露于SCH 900776,与Chk1 pS345快速的,剂量依赖性聚集相关,表明正常细胞的循环群诱导Chk1 pS345在暴露于SCH 900776后,是一部分无效循环,这也许通过AT-家族激酶和DNA-PK驱动 |
体内研究: |
相对于gemcitabine或SCH 900776单独给药,Gemcitabine给药30分钟后,4 mg/kg SCH 900776足以诱导γ-H2AX生物标志物,而8 mg/kg增强肿瘤药效动力学和退化响应。递增剂量的SCH 900776 (16 mg/kg和32 mg/kg)诱导肿瘤响应持续改进。重要的是,在BALB/c 小鼠体内,SCH 900776的剂量与强的生物标志物活化相关,而提高的肿瘤响应与gemcitabine对血液学指标增强的毒性无关. |
细胞实验: |
Cell lines: mESCs Concentrations: 10 μM Incubation Time: 1 h Method: Cells were treated with inhibitors or vehicle for 1 hour |
动物实验: |
Animal Models: 皮下注射A2780 或 MiaPaCa2细胞的额雌性裸鼠 Dosages: ~50 mg/kg Administration: 腹腔内注射 |
参考文献: |
1. Guzi TJ, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther, 2011, 10(4), 591-602. 2. Montano R, et al. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther, 2012, 11(2), 427-438. 3. Schenk EL, et al. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res, 2012, 18(19), 5364-5373. 4. Grow EJ, et al. p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models. Nat Genet. 2021 Aug;53(8):1207-1220. |
溶解性: |
Soluble in DMSO |
保存条件: |
-20℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
2.658 ml |
13.289 ml |
26.578 ml |
5 mM |
0.532 ml |
2.658 ml |
5.316 ml |
10 mM |
0.266 ml |
1.329 ml |
2.658 ml |
50 mM |
0.053 ml |
0.266 ml |
0.532 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |